Table 3.
The self-reported adverse reaction to the COVID-19 booster when comparing the homologous booster versus the heterologous booster.
| Characteristic | Homologous Booster | Heterologous Booster | p-Value | ||
|---|---|---|---|---|---|
| n = 246 (%) | 95% CI * | n = 934 (%) | 95% CI * | ||
| Some adverse reaction to booster | 222 (90.2%) | 86.5%, 94.0% | 822 (88.0%) | 85.9%, 90.1% | 0.300 |
| Duration of the reaction (days, median, IQR **) | 3 | (2, 3) | 3 | (2, 3) | 0.900 |
| Pain at injection site | 178 (72.4%) | 66.8%, 77.9% | 697 (74.6%) | 71.8%, 77.4% | 0.500 |
| Swelling or redness | 60 (24.4%) | 19.0%, 29.8% | 219 (23.4%) | 20.7%, 26.2% | 0.800 |
| Fatigue | 143 (58.1%) | 52.0%, 64.3% | 497 (53.2%) | 50.0%, 56.4% | 0.200 |
| Headache | 130 (52.8%) | 46.6%, 59.1% | 444 (47.5%) | 44.3%, 50.7% | 0.140 |
| Muscle or joint pain | 94 (38.2%) | 32.1%, 44.3% | 361 (38.7%) | 35.5%, 41.8% | 0.900 |
| Chills | 123 (50.0%) | 43.8%, 56.2% | 452 (48.4%) | 45.2%, 51.6% | 0.700 |
| Fever (≥37.5 °C) | 101 (41.1%) | 34.9%, 47.2% | 375 (40.1%) | 37.0%, 43.3% | 0.800 |
| Nausea or vomiting | 44 (17.9%) | 13.1%, 22.7% | 150 (16.1%) | 13.7%, 18.4% | 0.500 |
| Adenopathy | 27 (11.0%) | 7.07%, 14.9% | 145 (15.5%) | 13.2%, 17.8% | 0.072 |
| Insomnia | 18 (7.3%) | 4.06%, 10.6% | 97 (10.4%) | 8.43%, 12.3% | 0.150 |
| Malaise | 146 (59.3%) | 53.2%, 65.5% | 552 (59.1%) | 55.9%, 62.3% | >0.999 |
| Hives or rash | 2 (0.8%) | NA, 1.94% | 13 (1.4%) | 0.64%, 2.14% | 0.700 |
| Medical leave after booster | 57 (25.7%) | 19.9%, 31.4% | 151 (18.4%) | 15.7%, 21.0% | 0.016 |
| Potential life-threatening reaction to booster | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Perception of booster more reactogenic | 104 (46.8%) | 40.3%, 53.4% | 507 (61.7%) | 58.4%, 65.0% | <0.001 |
* 95% CI: 95% confidence interval. ** IQR: interquartile range.